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Background: Unwarranted administration of antibiotics in acute pancreatitis presents a global challenge.
The clinical reasoning behind the misuse is poorly understood. Our aimwas to investigate current clinical
practices and develop recommendations that guide clinicians in prescribing antibiotic treatment in acute
pancreatitis.
Methods: Four methods were used. 1) Systematic data collection was performed to summarize current
evidence; 2) a retrospective questionnaire was developed to understand the current global clinical
practice; 3) ﬁve years of prospectively collected data were analysed to identify the clinical parameters
used by medical teams in the decision making process, and ﬁnally; 4) the UpToDate Grading of Rec-
ommendations, Assessment, Development and Evaluation (GRADE) system was applied to provide evi-
dence based recommendations for healthcare professionals.
A. Parniczky et al. / Pancreatology 19 (2019) 488e499490Results: The systematic literature search revealed no consensus on the start of AB therapy in patients
with no bacterial culture test. Retrospective data collection on 9728 patients from 22 countries indicated
a wide range (31e82%) of antibiotic use frequency in AP. Analysis of 56 variables from 962 patients
showed that clinicians initiate antibiotic therapy based on increased WBC and/or elevated CRP, lipase and
amylase levels. The above mentioned four laboratory parameters showed no association with infection in
the early phase of acute pancreatitis. Instead, procalcitonin levels proved to be a better biomarker of early
infection. Patients with suspected infection because of fever had no beneﬁt from antibiotic therapy.
Conclusions: The authors formulated four consensus statements to urge reduction of unjustiﬁed anti-
biotic treatment in acute pancreatitis and to use procalcitonin rather than WBC or CRP as biomarkers to
guide decision-making.
© 2019 IAP and EPC. Published by Elsevier B.V. All rights reserved.Introduction
There is a general overuse of antibiotics (ABs) worldwide
resulting in AB resistance, which is part of the most remarkable
hazards to global health [1]. The misuse of AB has been associated
with fungal infection, Clostridium difﬁcile infection and increased
costs [2,3]. In 2009, approximately $10.7 billion was spent on
antibiotic therapy in the United States (US), including $6.5 billion in
the outpatient, $3.6 billion in acute inpatient care, and $526.7
million in long-term care settings [4]. According to the latest report
from Germany, the total amount of antimicrobials used in human
medicine is estimated to range between 700 and 800 tonnes per
year [5], 15% of its used by hospitals, while 85% in primary practice
[6]. European Surveillance of Antimicrobial Consumption Networks
report that antibiotic-resistant bacteria claim lives of approxi-
mately 700000 people each year globally [7]. The annual impact of
resistant infections is estimated to be $20 billion in excess health
care costs and 8 million additional hospital days in the US [8e10]
and over 1.6V billion and 2.5 million additional hospital days in the
European Union (EU) [11]. Antimicrobials currently account for
over 30% of hospital pharmacy budgets in the US [12].
The administration of ABs in acute pancreatitis (AP) has been
widely and thoroughly investigated [13]. We must note that either
direct pathologic insult of the pancreas i.e., alcohol, bile or fatty
acids [14], or increased autoactivation of trypsinogen [15] without
infection can activate inﬂammatory pathways, therefore AP itself is
not an indication for AB therapy [16,17]. Notably, current guidelines
do not recommend prophylactic AB therapy for the prevention of
infectious complications in AP (IAP/APA guideline, Grade 1B) [18],
(American College of Gastroenterology, strong recommendation,
moderate quality of evidence) [19]. However, in cases of proven
source of infection empiric administration of ABs is justiﬁed [20].
Based on the above mentioned suggestions we can calculate the
rate of ABs should be used in AP: pancreatic infection is a rare event
in AP (around 5%) [21], moreover there is only 14%e37.4% extra-
pancreatic indications (such as cholangitis or pneumonia) are re-
ported [22e25], therefore, the justiﬁed rate of ABs use should be
between 20 and 40% in AP.
However, the Hungarian Pancreatic Study Group (HPSG) found
that 77.1% of the total study population (n¼ 600) received AB
therapy and two thirds of this group had no signs of infection,
meaning AB treatment was administered on a preventive basis [25].
In population-based studies,14% of patients received unjustiﬁed (so
called prophylactic) AB in Portugal [26], 25.5% in Canada [27],
27e58% in the USA [28], 30.7% in the UK [23], 81.4% in India [29],
44.6e69.3% [30] and 74.3% in Japan [31].
There could be several reasons behind AB overuse worldwide:
1) The guideline is insufﬁcient regarding AP therapy. It only states
that intravenous AB prophylaxis is not recommended for the pre-
vention of infectious complications in AP (GRADE 1B, strongagreement), failing to offer indication for proper AB treatment [18].
2) Misinterpretation of inﬂammatory biomarkers, such as C reac-
tive protein (CRP) during AP [26]. It has been suggested that
elevation of CRP can have major inﬂuence on prescribing prophy-
lactic ABs in AP [26]. 3) Non-adherence to guidelines [13]. Several
studies reported moderate or non-compliance to the recommen-
dations for the management of AP [23,27,29,32e36]. 4) Defensive
medical care in which healthcare providers try to protect them-
selves from malpractice claims [37e39].
These data clearly suggest the crucial importance of multicentre,
multinational studies aiming to give proper recommendations for
AB utilization in AP.
The speciﬁc aims of this study were to (1) summarize current
evidence, (2) understand the current global practice, (3) under-
stand the clinical parameters used bymedical teams in the decision
making process, (4) verify the usefulness of these parameters, (5)
make more informed recommendations for healthcare
professionals.Methods
1. Systematic review
The systematic review aimed to summarize the recent evidence
(1) on the guidance of AB therapy and (2) on the strategies how
high-quality studies raised the suspicion of pancreatic infection in
AP. We observed the rules of Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) 2009 guideline
when reporting this work [40].Eligibility
Eligible randomized controlled trials (RCTs) discussed (1) pa-
tients diagnosed with AP (2) who were given any ABs orally and/or
intravenously (3) with available full-text of any languages. Studies
applying continuous regional arterial infusion or other drugs (e.g.,
protease inhibitors) were excluded. We chose the inclusion of RCTs
on the guidance of AB therapy or preventive AB therapy because
high-quality studies centered around the suspicion of pancreatic
infection are lacking. Our assumption that the best evidence on the
topic might be present in these studies relies on two arguments. On
one hand, deﬁnitive infection and infected pancreatic necrosis are
high-priority hard outcomes of these studies focusing on infection
control. On the other hand, suspicion of infection is a safety issue in
these studies because of the required immediate intervention, such
as a change in per protocol drug regime or a surgical/radiological
approach.
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We searched cited and citing articles, including previous meta-
analysis and systematic reviews, of relevant reports for eligible
studies. We did not contact the authors of original studies for
information.
We conducted a comprehensive systematic search in MEDLINE
(PubMed), EMBASE, and Cochrane Trials from inception up to 7 July
2018 for articles reporting on the use of antibiotics in AP. We
applied the following query without any ﬁlters imposed on the
search: pancreatitis AND (antibiotic OR antibiotics OR carbapenem
OR imipenem OR meropenem OR ertapenem OR doripenem OR
aminoglycoside OR amikacin OR gentamicin OR cephalosporin OR
cefepime OR ceftriaxone OR ceftazidime OR cefoperazone OR
ceﬁxime OR cefuroxime OR cephalexin OR ceftobiprole OR cefa-
zolin OR cefalotin OR glycopeptide OR vancomycin OR teicoplanin
OR penicillin OR amoxicillin OR ampicillin OR oxacillin OR piper-
acillin OR mezlocillin OR ticarcillin OR sulbactam OR tazobactam
OR clavulanate OR ﬂuoroquinolone OR ciproﬂoxacin OR levo-
ﬂoxacin OR moxiﬂoxacin OR oﬂoxacin OR peﬂoxacin OR metroni-
dazole OR tigecycline OR linezolid OR daptomycin).
Yield of search was combined in reference manager software
(EndNote X7.4, Clarivate Analytics, Philadelphia, PA, US) to remove
overlaps between databases and duplicates, then, two independent
investigators screened the records by title, abstract, and full-texts
against our eligibility criteria in duplicate. Discrepancies were
resolved by third party arbitration.
Data collection
A pre-constructed data collection table was designed by our
research team. After this step, training was organized to increase
the consistency of data collection. Data were extracted by two in-
dependent review authors in duplicate. Discrepancies were
resolved by a consensus meeting of our research team.
The following data were extracted: publication data (authors,
year), setting (country, centres, setting), deﬁnition and etiology of
AP, eligibility criteria of the study, the total number of patients (in
intention to treat and per protocol analyses), and interventions
(drug regimens and/or guidance of therapy). In addition, deﬁnitions
of suspected and deﬁnitive pancreatic and extrapancreatic in-
fections, and the consequent clinical management were collected.
2. Retrospective data analysis
To assess the worldwide trends in administration of AB we sent
a letter of invitation and a questionnaire to the member of the In-
ternational Association of Pancreatology in November 2017. Col-
leagues have provided data from their past-year inpatients’ practice
accordingly to gender, etiology, mortality and severity of AP, and AB
therapy irrespectively from its indication. Percentage of AB treat-
ments was calculated, and it has been illustrated on a colour scaled
map.
3. Prospectively collected data analysis
The Hungarian Pancreatic Study Group (HPSG) (https://tm-
centre.org/en/study-groups/hungarian-pancreatic-study-group/)
was established in 2011 with the aim to improve patients’ care in
pancreatic disease. We have developed an international, uniform
and prospective electronic data registry to collect high quality data
from patients suffering from AP. From January 1, 2013 to November
30, 2016, 1070 episodes of AP have been enrolled. Centre distri-
bution is indicated in Supplementary Fig. 1. Diagnosis of AP was
based on the A1 recommendation of the IAP/APA guideline. Two ofthe following alterations were conﬁrmed in each patient: abdom-
inal pain (clinical symptom), pancreatic enzyme elevation at least
three times above upper limit andmorphological changes (imaging
techniques).
Four quality control points were established in our registry. First,
the local clinical research assistant electronically uploads the data
and conﬁrms equivalency with the hard copy. Second, the local
institutional principal investigator (who holds a medical doctoral
degree) double-checks the uploaded data and conﬁrms the validity
and accuracy. Third, the central data administrator, who is based at
the headquarters of HPSG, controls the accuracy and ﬁnally (in
house monitor), the registry leader reviews the presented data and
veriﬁes them. Patients with inadequate or insufﬁcient data are
excluded.
To answer our post hoc deﬁned research question, data from
HPSG pancreatic registry were analysed. We selected 56 parame-
ters relating to our research question (Supplementary Fig. 2.). Those
patients’ data were used for further analysis where the following
information were available in its entirety: age, gender, length of
hospitalization, severity, based on revised Atlanta classiﬁcation,
mortality, complications and details about AB therapy (starting
date, type of antibiotics, etc.) [17]. Data of 962 patients met the
criteria mentioned above, so this cohort was used for further
analysis.
The following groups have been designated. Patients in Group1
and 2 did not receive AB therapy. Patients in Group 1 did not receive
AB therapy and their no symptoms or evidence of infection. Pa-
tients in Group 2 did not receive AB treatment either, however,
there were symptoms which may associated with infection (ie.
fever) or the followings were declared: positive bacterial culture,
cholangitis, upper or lower respiratory tract infection, urogenital
infection, and infection of any other organ system.
Members of Group 3, 4 and 5 all received AB treatment. In Group
3, patients had no features characteristic of infection, therefore
received AB as prevention. In these patients there were no signs of
infection or negative bacterial culture. Patients in Group 4 received
empirical AB therapy since they had features characteristic of
infection (with no (a) or negative bacterial culture (b)). Group 5
patients took AB as a targeted therapy following positive bacterial
culture, specifying the exact cause of infection and/or gas in and/or
around the pancreas on CECT or MRI.
Statistical analysis
For descriptive statistics, the number of patients, mean, stan-
dard deviation (SD), standard error of mean (SEM), minimum,
median and maximum values were calculated for continuous var-
iables, and the case number and percentage were computed for
categorical values.
For inferential statistics, the following tests were applied to
determine statistical signiﬁcance of differences between groups. To
compare two groups of independent samples, the t-test was used
for normally distributed data and the Mann-Whitney U test for
non-normally distributed data. To compare more than two groups,
one-way ANOVA followed by the Tukey post hoc test was employed
for normally distributed data with homogenous group-wise stan-
dard deviation; Brown-Forsythe Levene-type test was applied to
test of variance homogeneity; the Welch test followed by the
Games-Howell post hoc test for normally distributed data with
heterogeneous group-wise standard deviation; and the Kruskal-
Wallis test followed by the Holm p-value adjustment method for
non-normally distributed data.
The association between categorical variables was inspected by
the Chi-square test and Fisher's exact test. To compare proportions
for more than two groups, the pairwise proportion test followed by
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differences were deﬁned in all cases.
The relevant statistical tests are also described in the legends to
the ﬁgures. Statistical analyses were performed using SPSS (Version
23, IBM, New York, NY, USA) and R Studio (Version 1.1.453, fmsb
package).
The authors have read the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) State-
mentdchecklist of items, and the manuscript was prepared and
revised accordingly [41].
4) Development of evidence based recommendationsGrading
Strength of recommendation and quality of evidence were
based on the guideline of the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) Working
Group, an internationally accepted system established in 2011
(https://www.uptodate.com/home/grading-tutorial#). Strength of
any recommendation depends on the establishment between
beneﬁts and risks and burden. Three-category has been imitated for
quality of evidence regarding treatment effect. All authors deter-
mined the strength of the consensus by voting yes or no: 95% or
more ‘yes’ votes¼ ‘full agreement’; at least 70% ‘yes’ votes¼ ‘strong
agreement’, and more than 50% ‘yes’ votes¼ ‘weak agreement’.
5) Ethics
The study was approved by the Scientiﬁc and Research Ethics
Committee of the Medical Research Council (22254e1/2012/EKU).
All participants provided written consent of participation to this
study. The ethics committee carefully checked and approved the
consent procedure.
Results
There is no consensus on the start of AB therapy in patients with no
bacterial culture test
Supplementary Figure 3 shows the ﬂowchart of this systematic
review. After careful selection, only 1 RCT reporting on the guidance
of AB therapy was eligible for inclusion [42]. In this study, pro-
calcitonin (PCT)-guided (>0.5 ng/ml) AB regime proved to be su-
perior over 2-week prophylactic AB treatment in severe AP
(Supplementary Fig. 4). We identiﬁed 22 studies [42e63] reporting
on prophylactic antibiotic treatment in AP. Severe AP/acute necro-
tizing pancreatitis were analysed in 18 of 22 studies, however, these
entities were deﬁned in many forms: 9 and 11 studies incorporated
CRP (ranging from >100 to >200mg/l) and pancreatic necrosis
(conﬁrmed by CT or FNA) into the deﬁnitions Supplementary Fig. 5.
Despite the inclusion of RCTs, the way how the studies deﬁned the
suspicion of an infection was vague. Factors taken into consider-
ationwere, as follows: CRP (5 studies), fever (generally in 5 studies,
2 of them considered persistent fever only), criteria of SIRS/organ
failure/sepsis (3 studies), air bubbles in necrosis on CT (2 studies),
and leukocytosis (2 studies). Only 2 studies suspected an infection
when a rise in inﬂammatory markers occurred following an initial
decrease. Interestingly, neither of the studies testing prophylactic
ABsmentioned PCT, as amarker of infection in the included studies.
The general approach proved a suspected infection was FNA and
culturing in most cases followed by surgery as a treatment. A
change in drug regime was managed either empirically and/or by
culturing.Antibiotics are overused worldwide
9869 patients’ data were collected from 23 countries and it
showed a global overuse of ABs. The highest rates of AB therapy
could be seen in Asia (China 81.4%, Taiwan 80.6%) and Eastern
Europe (Albania 78.6%, Bulgaria 78%), whereas the lowest rates are
observed in Western Europe (Spain 31.8%, United Kingdom 31.2%)
(Fig. 1). There is no association between the rate of AB therapy and
the outcome (mortality, severity) of the disease between the
countries. The details of centres and countries can be found in
Supplementary Fig. 6.
There is a large detection bias in the initiation of AB therapy and
bacterial culture test
In these series of data analysis we aimed to understand the
decision making process of physicians concerning the initiation of
AB therapy in AP. 962 of 1070 prospectively collected patients in the
HPSG AP registry had details concerning AB therapy. Firstly, we
conﬁrmed that the registry represents a normal distribution of AP
concerning age, gender, etiology, length of hospitalization (LOH),
severity and mortality (Supplementary Fig. 7). Secondly, we per-
formed the analysis on the major outcome parameters (LOH,
severity and mortality) and found that (i) worse LOH, severity and
mortality parameters are associated with AB treatment, (ii) holding
off the AB therapy among patients with suspected infection (Group
2) is not associated with poor outcome, (iii) patients having bac-
terial culture (Group 4b) test had signiﬁcantly worse outcome than
patients having no bacterial test (Group 4a) among AB treated
groups, (iv) conﬁrmed infection had the worst outcome in AP
(Group 5) (Fig. 2A and B) (v) the willingness of the initiation of AB
therapy elevates parallel with the severity and ﬁnally (vi) the
highest level of AB therapy is in biliary AP (Fig. 2C).
90% of AB therapy started in the ﬁrst 3 days of AP
74% of AB are started on Day 1, 10.5% on Day 2, whereas 6.0% on
Day 3 (Supplementary Fig. 8A). Early AB treatment had no associ-
ation either with shorter AB administration (Supplementary
Fig. 8D), or with the outcome of AP (Supplementary Figs. 8E and
J). Administration of three different ABs (Supplementary Figs. 8B,
F, G, K) or higher number of changes in the AB regime
(Supplementary Figs. 8C, H, I, L) are associated with longer AB
therapy and worse outcome of the disease suggesting that if pa-
tients’ condition do not improve during AB therapy or bacterial
resistance occurs doctors initiate AB therapy changes. Detailed
statistics can be found in Supplementary Fig. 9. In 52% of the cases
single AB, in 43.7% double AB, whereas in 4.3% three or more AB
were administered. In the single AB group cephalosporin 29.5%,
whereas in the double AB group ciproﬂoxacin and metronidazole
were the most commonly chosen therapies (Supplementary
Fig. 10). Of course a cohort analysis is not enable to differentiate
between the drugs, but not surprisingly imipenem or not conven-
tional AB therapies were associated with more severe pancreatitis
and higher mortality (Supplementary Fig. 10). Detailed statistics
can be found in Supplementary Fig. 11.
Elevated CRP level, white blood cell (WBC) count, lipase and amylase
levels are the biomarkers used for the initiation of AB therapy
We investigated the four most commonly monitored laboratory
markers (amylase, lipase, C-reactive protein, WBC count) during
the course of AP. Mean levels of these parameters on the starting
day of AB therapy were compared. The amylase and lipase levels
showed association with the AB treatment, but as we expected, not
Fig. 1. Map of antibiotic use worldwide. There is a general overuse of AB worldwide (57.2%). The highest rates of AB therapy are in Asia (China 81.4%, Taiwan 80.6%) and Eastern
Europe (Albania 78.6%, Bulgaria 78%), whereas the lowest rates are observed in Western Europe (Spain 31.8%, United Kingdom 31.2%).
Fig. 2. Grouping of patients based on sign of infection, antibiotic (AB) treatments and microbiology examination. General characterisation of AB administration, length of
hospitalization (LOH) and mortality. Based on the AB treatment patients were divided into two main groups (non-AB and AB) and six subgroups. Group 1: Patients had no sign of
inﬂammation and did not received ABs. Group 2: Patients had sign of inﬂammation (fever, imaging alterations, etc.) but did not received ABs. Group 3: Patients had no sign of
inﬂammation but received preventive ABs. Group 4a: Patients had sign of inﬂammation (fever, imaging alterations, etc.) and received antibiotics, however no microbiology culture
was requested. Group 4b: Patients had sign of inﬂammation (fever, imaging alterations, etc.) and received antibiotics. Microbiology culture was done but no pathogen bacteria were
found. Group 5: Patients had sign of inﬂammation (fever, imaging alterations, etc.), microbiology culture was performed with positive results and received AB treatment. A. LOH was
signiﬁcantly longer in AB therapy groups then in non-AB groups. (13.4± 0.5 days vs 8.3± 0.3 days, p< 0.001) In presence of suspected infection (Group 2) LOH (8.3± 0.4 days vs
8.2± 0.4 days), severity and mortality were the same as in Group 1. Preventive AB therapy (Group 3) resulted signiﬁcantly longer hospitalization compare to Group 1 (12.3± 1.1 days
vs 8.3± 0.4 days, p< 0.001). Signiﬁcantly more patients with moderate (220/718 vs 46/244, p< 0.001) and severe disease (50/718 vs 3/244, p< 0.001) course received AB therapy.
There was no signiﬁcant difference in mortality between the groups. B. If we retracted Group 5 (patients with proven infection), the rate of AB therapy still remained signiﬁcantly
high in moderate and severe AP (p< 0.001, p¼ 0.023). C. AB treatment in context of etiology of AP.
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signiﬁcantly higher inﬂammatory markers (CRP and WBC) were
associated with the AB treatment and more severe AP (Fig. 3CeD,
G-H).
Elevation of PCT level but not CRP, WBC, lipase or amylase levels are
associated with infection in the early phase of AP
CRP levels progressively increase, whereasWBC values decrease
during the ﬁrst 3 days of AP irrespectively of AB therapy in either
suspected (Group 4a and b) or in conﬁrmed (Group 5) infection (Fig
4A, F). Suspected infection (Group 2) did not show difference in CRP
and WBC levels compared to Group 1 among the non-AB groups
(Fig. 4B, G). Preventive AB therapy (Group 3) was administered in
patients with signiﬁcantly higher CRP and WBC levels (p< 0.001,
p¼ 0.046), however, both CRP and WBC level decreased nearly the
same level as Group 1 by day 5 (Fig. 4C, H). Bacterial culture test
(Group 4b) was performed in patients with signiﬁcantly higher CRP
(p¼ 0.008) (Fig. 4D). These data are in accordance with the results
at the start of AB therapy in AP (Fig. 3.). Very importantly, neither
CRP nor WBC showed differences between patients having positive
blood culture (Group 5) vs. patients having negative blood culture
tests (group 4b), suggesting that CRP and WBC have no association
with infection at the early phase of AP (Fig. 4E, J, L, M). However,
PCT level, as conﬁrmed in earlier studies showed correlation with
infection (Fig. 4K, N) with acceptable sensitivity and speciﬁcityFig. 3. Most commonly monitored laboratory markers on starting day of AB therapy.
calculated on starting day of AB therapy. In non-AB groups day-matched controls were sel
(1004.15± 50.22 U/L) has been signiﬁcantly differed (p< 0.001). B. There has been a signiﬁca
(2298.72± 207.82 U/L) groups. C. CRP showed a signiﬁcant difference between non-AB and
detected with regards to WBC levels (10.32± 0.28 G/L vs 13.8± 0.2 G/L, p< 0.001 (D). E. Aver
(2303.05 ± 219.19 U/L, 2286.82 ± 378.21 U/L, 2131.42± 1377.75 U/L) did not differ between s
G. Average CRP (68.77± 4.32mg/L, 104.56± 8.71mg/L, 181.7 ± 27.26mg/L) and WBC (H) (12.8
AP (mild-moderate: p¼ 0.007 and p< 0.001, moderate-severe: p¼ 0.012 and p¼ 0.22).(AUC:0.73). Fig. 5 shows the changes of amylase and lipase during
AP. It is very clear that neither infection (Group 2) nor AB treatment
(Group 3, 4 and 5) change the pattern of enzyme levels during AP.Pancreatic infection causes the worst outcome in AP
Here we correlated the disease outcome with the infected or-
gans. Biliary, respiratory, urogenital infection or elevated PCT or
fever alone with no identiﬁed organ infection resulted in a mod-
erate severity range (8.3%e14.3%) without mortality, however
pancreatic infection caused 25% severe AP with extremely high
mortality rate (25%), (Fig. 6). Detailed statistics can be found in
Supplementary Fig. 12.Increase in the pathogen numbers is associated with the worse
outcome of AP
The most common pathogens were Staphylococci (34.2%),
Enterococci (27.4%), Clostridium difﬁcile (22.4%), Escherichia coli
(18.4%) and Pseudomonas (13.2%). Due to the relatively low event
rates, we could not analyse the differences among pathogens,
however, it was obvious that increased numbers of detected
pathogens strongly correlates with worse outcomes in AP
(Supplementary Fig. 13).Average amylase, lipase, C-reactive protein (CRP) and white blood cells (WBC) were
ected. A. Average amylase in non-AB group (510.01± 57.91 U/L) compare to AB group
nt difference (p< 0.001) between average lipase in non-AB (815.83± 96.73 U/L) and AB
AB groups (52.16± 4.91mg/L vs 86.4± 4.2mg/L, p< 0.001) similar trends have been
age amylase (1015.25± 55.10 U/L, 957.41± 83.33 U/L, 1077.48 ± 397.02 U/l and lipase (F)
everity groups (mild-moderate: p¼ 0.26, p¼ 0.16; moderate-severe: p¼ 0.16, p¼ 0.15).
3 ± 0.21 G/L, 15.11± 0.49 G/L, 16.5± 0.98 G/L) levels showed correlation with severity of
Fig. 4. Trends in the changes of CRP and WBC during the early phase of AP. A. Due to the inﬂammation of the pancreas, irrespectively from the infection CRP levels rose during
the ﬁrst 3 days. F. Non-similar trend can be seen in WBC levels. B and G. Suspected infection (Group 2) in AP did not show difference (p¼ 0.431, p¼ 0.923) in cumulative average
(cAVE) of CRP (70.33± 6.31mg/L) and cAVE of WBC levels (10.82± 0.47 G/L) compare to Group 1 (57.12± 5.50 U/L, 10.14± 0.29 G/L). C and H. Preventive AB therapy (Group 3) was
administered in patients with signiﬁcantly higher CRP (104.69± 8.05mg/L) and WBC levels (11.71± 0.40 G/L) (p¼<0.001 and p¼ 0.046, respectively), however we observed the CRP
increase, then drop at day 3 and decreased nearly the same level as Group 1 by the day 5. D and I. Bacterial culture (Group 4b) was performed in patients with signiﬁcantly higher
CRP (102.90 ± 3.88mg/L vs 141.05± 8.66, p< 0.001). E. and J. Proven infection (Group 5) did not result in signiﬁcant difference in CRP andWBC levels in the ﬁrst ﬁve days. K: cAVE of
PCT differ signiﬁcantly between Group 4b and Group 5 (p¼0.026). L, M and N. CRP (AUC: 0.51) and WBC (AUC: 0.45) failed, however PCT (AUC: 0.73) fairly can predict infection in
AP.
A. Parniczky et al. / Pancreatology 19 (2019) 488e499 495Consensus statements
Based on the systematic review and retrospective and pro-
spective data analysis, the authors from 62 centres/23 countries
accepted the following statements and recommendations as
amendments to the current guidelines (Table 1.)Statement 1: There is a general overuse of ABs in AP, therefore,
centres should make a strong effort to reduce it to a justiﬁable
level (GRADE 1C: strong suggestion, low quality evidence, full
agreement)
Statement 2: CRP and WBC values are not associated with
infection in the early phase of AP, therefore CRP andWBC should
not be used as biomarkers for decision making concerning AB
Fig. 5. Trends in the changes of amylase and lipase during the early phase of AP. There are no signiﬁcant differences between the groups.
A. Parniczky et al. / Pancreatology 19 (2019) 488e499496therapy in the early phase of AP (GRADE 1C: strong suggestion,
low quality evidence, full agreement).
Statement 3: Progressive elevation of CRP is part of the in-
ﬂammatory response in AP, therefore, an upward trend of CRP
levels should not be an indicator for AB treatment in the early
phase of AP (GRADE 1C: strong suggestion, low quality evidence,
full agreement).
Statement 4: Elevation of PCT levels during the early phase of
AP is associated with infection, therefore, it can guide the choice
to start AB treatment in the absence of proven infection (GRADE
2C: weak suggestion, low quality evidence, full agreement).Discussion
At the beginning of our study, we performed a systematic re-
view in which we showed that (i) PCT can be a good marker for
suspected infection (ii), there is no consensus concerning the
compulsory start of AB therapy in patients with no positive bac-
terial culture test, (iii) patients having necrosis have no beneﬁts
from AB therapy. These data have predicted the results of our in-
ternational retrospective data analysis, which showed that
administration of ABs widely differs between countries.Generally, in Western European countries less AB is adminis-
tered, whereas Eastern European and Asian countries are the most
frequent users of AB. Our data are in accordance with several na-
tional surveys performed in the past two decades. In Germany, 47%
of respondents use AB prophylaxis [32] and 44% of the doctors al-
ways administer AB in cases of severe AP [33]. In the UK and
Ireland, 24% use prophylaxis in AP regardless of the severity [64].
Prophylactic AB treatment is utilized by 73% of the European
members of the International Hepato-Pancreato-Biliary Association
[65]. 40.9% of the interviewed American clinicians give AB in more
than 75% of patients with severe AP [35]. In Japan, before the
publication of the Japanese evidence-based guidelines in 2003,
82.5% of the physicians used AB prophylaxis after the publication
76.1% [34], which is still a frequent practice pattern, considering
that the Japanese guidelines also endorse routine use of AB pro-
phylaxis in mild to moderate AP [66,67]. These data show without
proper guideline, the physicians’ willingness of AB therapy is very
high. The high rate of AB treatment can also be explicable with the
fact that the death rate can increase from 2 to 35% due to bacterial
infection of the necrotic pancreatic tissue [25,68] Organ failure
alone was associated with a mortality of 19.8% [68,69], whereas,
infected necrosis without organ failure has low mortality [70].
Based on these observations, it is not surprising that several trials
Fig. 6. Source of infection in AP. Infection of the pancreas extended the length of hospitalization (LOH) to 25.55± 4.76 days, deteriorated the course of the disease (moderate 25%,
severe 75%) and elevated the mortality to 25%. PIe charts represent the distribution of mild (green), moderate (yellow) and severe (red) cases in each group of AP patients.
Table 1
Summary of the consensus statements.
Statements Grade of
evidence
Level of
agreement
1 There is a general overuse of antibiotics in AP, therefore, centres should make a strong effort to reduce it to a justiﬁable level. 1C full (99%)
2 CRP andWBC values are not associated with infection in the early phase of AP, therefore CRP andWBC should not be used as biomarkers
for decision making concerning AB therapy in the early phase of AP.
1C full (97%)
3 Progressive elevation of CRP is part of the inﬂammatory response in AP, therefore, an upward trend of CRP levels should not be an
indicator for AB treatment in the early phase of AP.
1C full (97%)
4 Elevation of PCT levels during the early phase of AP is associated with infection, therefore, it can guide the choice to start antibiotic
treatment in the absence of proven infection.
2C full (96%)
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preventive AB in AP [44,49,53,54,56,57,59,61,71]. A recently pub-
lished Cochrane review showed that neither of the preventive AB
treatments decreased short-term mortality in AP [72].
The most important goals of our study were (i) to ﬁnd out whatparameters mislead physicians during the initiation of AB therapy
(ii) to ﬁnd a biomarker(s), which can predict infection without
bacterial culture test. In this investigation we showed with several
analysis that elevation of amylase, lipase levels, CRP and WBC
mislead the doctors decisionmaking on the initiation of AB therapy.
A. Parniczky et al. / Pancreatology 19 (2019) 488e499498CRP and WBC have been conﬁrmed to be strongly associated with
the severity of AP [73e75] however, data on lipase and amylase are
contradictory [76e79]. In our study, the initiation of AB therapy
was based on the severity and most probably on a predicted
infection diagnosed by the elevation of inﬂammatory biomarkers
namely the CRP andWBC. Here we conﬁrmed that these laboratory
parameters have no association with infection, but PCT, which
showed correlation with infection with acceptable sensitivity and
speciﬁcity.
Finally, based on the systematic review and the retrospective
and prospective cohort analyses, the participants of this trial
accepted important statements and recommendations as amend-
ments to the current guidelines. The authors strongly believe that
the evidence and consensus statements presented in this article
will signiﬁcantly decrease unnecessary AB therapy in AP
worldwide.
Authors contribution
P. Hegyi and A. Parniczky formulated the research questions and
designed the study. F. Izbeki, L. Gajdan, A. Halasz, A. Vincze, I. Szabo,
G. Par, J. Bajor, P. Sarlos, J. Czimmer, J. Hamvas, T. Takacs, Z. Szepes, L.
Czako, M. Varga, J. Novak, B. Bod, A. Szepes, J. Sümegi, M. Papp, Cs.
Gog provided patients’ data to the Hungarian Pancreatic Registry.
They have also controlled the quality of the data.
Zs. Szakacs and A. Parniczky performed the systematic review.
W. Huang, Q. Xia, P. Xue, W. Li, W. Chen, N. V. Shirinskaya, V. L.
Poluektov, A. V. Shirinskaya, P. Hegyi Jr., M. Batovský, J. A.
Rodriguez-Oballe, I. M. Salas, J. Lopez-Diaz, J. E. Dominguez-Munoz,
X. Molero, E. Pando, M. L. Ruiz-Rebollo, B. Burgue~no-Gomez, Y.
Chang, M. Chang, A. Sud, D. Moore, R. Sutton, A. Gougol, G. I.
Papachristou, Y. Mykhailovych Susak, I. Olehovych Tiuliukin, A. P.
Gomes, M. J. Oliveira, D. J. Aparício, M. Tantau, F. Kurti, M.
Kovacheva-Slavova, S. Stecher, J. Mayerle, G. Poropat, K. Das, M. V.
Marino, G. Capurso, E. Małecka-Panas, H. Zatorski, A. Gasiorowska,
N. Fabisiak, P. Ceranowicz, B. Kusnierz-Cabala, J. R. Carvalho, S. R.
Fernandes, J. H. Chang, E. Kwang Choi, J. Han, S. Bertilsson, H. Jumaa,
G. Sandblom, S. Kacar, M. Baltatzis, A. V. Varabei, V. Yeshy, S.
Chooklin, A. Kozachenko, N. Veligotsky provided retrospective data
about the antibiotic therapy in acute pancreatitis in their centre.
E.M Toth, Zs. Szakacs, Sz. Godi, R. Hagendorn, D. Illes, B. Koncz, K.
Marta, A. Miko, D. Mosztbacher, B.Cs Nemeth, D. Pecsi, A. Szabo, A.
Szücs, P. Varjú, A. Szentesi, E. Darvasi, B. Er}oss contributed to the
study implementation, data acquisition and quality control of the
prospectively collected data, A. Parniczky, E.M Toth, P. Hegyi
interpreted the data, T. Lantos performed the statistical analysis, A.
Parniczky, E.M Toth, T. Lantos with the technical help of K. Marta
constricted the ﬁgures.
A. Parniczky and P. Hegyi wrote the article, all authors have read,
approved the ﬁnal manuscript and have been involved in the
consensus voting.
Acknowledgements
The study was supported by Project Grants (KH125678 and
K116634 to PH, K120335 to TT), the Economic Development and
Innovation Operative Programme Grant (GINOP 2.3.2-15-372 2016-
00048 to PH) and Human Resources Development Operational
Programme Grant (EFOP-3.6.2-16-2017-00006 to PH) from the
National Research Development and Innovation Ofﬁce, by a Mo-
mentum Grant from the Hungarian Academy of Science (LP2014-
10/2014 to PH), by the Janos Bolyai Research Scholarship of the
Hungarian Academy of Sciences (to AP) and the ÚNKP-18-4 new
national excellence program of theministry of human capacities (to
AP). Data from Liverpool (by AS, DM, RS) were obtained throughsupport from the NIHR Biomedical Research Unit funding scheme.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.pan.2019.04.003.
Financial or ethical conﬂict of interest
Authors disclose any ﬁnancial or ethical conﬂict of interest.
References
[1] Ventola CL. The antibiotic resistance crisis: Part 1: causes and threats. PT
2015;40:277e83.
[2] Ping H, BiRong D, BinYou W, GuanJian L, ChangQuan H, XiaoFang L, et al.
Invasive fungal infections in elderly patients receiving antibiotic treatment: an
8-year retrospective study. J Am Geriatr Soc 2009;57:936e7.
[3] Bernatz JT, Safdar N, Hetzel S, Anderson PA. Antibiotic overuse is a major risk
factor for clostridium difﬁcile infection in surgical patients. Infect Control
Hosp Epidemiol 2017;38:1254e7.
[4] Suda KJ, Hicks LA, Roberts RM, Hunkler RJ, Danziger LH. A national evaluation
of antibiotic expenditures by healthcare setting in the United States, 2009.
J Antimicrob Chemother 2013;68:715e8.
[5] Report on the consumption of antimicrobials and the spread of antimicrobial
resistance in human and veterinary medicine in Germany. 2016.
[6] Meyer E, Gastmeier P, Deja M, Schwab F. Antibiotic consumption and resis-
tance: data from europe and Germany. Int J Med Microbiol 2013;303:388e95.
[7] Summary of the latest data on antibiotic consumption in the European Union.
2017. p. 2017. november.
[8] Antibiotic resistance threats in the United States, 2013. 2013.
[9] World health day. Media fact sheet. 2011.
[10] The bacterial challenge: time to react. A call to narrow the gap between
multidrug-resistant bacteria in the eu and the development of new antibac-
terial agents. 2009.
[11] Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect
Med Chem 2014;6:25e64.
[12] Sipahi OR. Economics of antibiotic resistance. Expert Rev Anti Infect Ther
2008;6:523e39.
[13] Baltatzis M, Jegatheeswaran S, O'Reilly DA, Siriwardena AK. Antibiotic use in
acute pancreatitis: global overview of compliance with international guide-
lines. Pancreatology 2016;16:189e93.
[14] Hegyi P, Petersen OH. The exocrine pancreas: the acinar-ductal tango in
physiology and pathophysiology. Rev Physiol Biochem Pharmacol 2013;165:
1e30.
[15] Nemeth BC, Szücs A, Hegyi P, Sahin-Toth M. Novel PRSS1 Mutation p.P17T
validates pathogenic relevance of CTRC-mediated processing of the trypsin-
ogen activation peptide in chronic pancreatitis. Am J Gastroenterol. 2017
Dec;112(12):1896e8.
[16] Sah RP, Dawra RK, Saluja AK. New insights into the pathogenesis of pancre-
atitis. Curr Opin Gastroenterol 2013;29:523e30.
[17] Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al.
Classiﬁcation of acute pancreatitis–2012: revision of the atlanta classiﬁcation
and deﬁnitions by international consensus. Gut 2013;62:102e11.
[18] Iap/apa evidence-based guidelines for the management of acute pancreatitis.
Pancreatology 2013;13:e1e15.
[19] Aga institute medical position statement on acute pancreatitis. Gastroenter-
ology 2007;132:2019e21.
[20] Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gas-
troenterol 2006;101:2379e400.
[21] Buchler MW, Klar E. Introduction. Complications of pancreatic surgery and
pancreatitis. Dig Surg 2002;19:123e4.
[22] Nesvaderani M, Eslick GD, Faraj S, Vagg D, Cox MR. Study of the early man-
agement of acute pancreatitis. ANZ J Surg 2017;87:805e9.
[23] Baltatzis M, Mason JM, Chandrabalan V, Stathakis P, McIntyre B,
Jegatheeswaran S, et al. Antibiotic use in acute pancreatitis: an audit of cur-
rent practice in a tertiary centre. Pancreatology 2016;16:946e51.
[24] Besselink MG, van Santvoort HC, Boermeester MA, Nieuwenhuijs VB, van
Goor H, Dejong CH, et al. Timing and impact of infections in acute pancreatitis.
Br J Surg 2009;96:267e73.
[25] Parniczky A, Kui B, Szentesi A, Balazs A, Szucs A, Mosztbacher D, et al. Pro-
spective, multicentre, nationwide clinical data from 600 cases of acute
pancreatitis. PLoS One 2016;11:e0165309.
[26] Cardoso FS, Ricardo L, Gondar P, Deus JR, Horta D. C-reactive protein may
inﬂuence decisively the prescription of prophylactic antibiotics in acute
pancreatitis: a population-based cohort study. Pancreas 2015;44:404e8.
[27] Greenberg JA, Hsu J, Bawazeer M, Marshall J, Friedrich JO, Nathens A, et al.
Compliance with evidence-based guidelines in acute pancreatitis: an audit of
practices in university of toronto hospitals. J Gastrointest Surg 2016;20:
392e400.
[28] Koutroumpakis E, Slivka A, Furlan A, Dasyam AK, Dudekula A, Greer JB, et al.
A. Parniczky et al. / Pancreatology 19 (2019) 488e499 499Management and outcomes of acute pancreatitis patients over the last
decade: a us tertiary-center experience. Pancreatology 2017;17:32e40.
[29] Murata A, Matsuda S, Mayumi T, Yokoe M, Kuwabara K, Ichimiya Y, et al.
A descriptive study evaluating the circumstances of medical treatment for
acute pancreatitis before publication of the new jpn guidelines based on the
Japanese administrative database associated with the diagnosis procedure
combination system. J Hepatobiliary Pancreatol Sci 2011;18:678e83.
[30] Hamada S, Masamune A, Shimosegawa T. Transition of early-phase treatment
for acute pancreatitis: an analysis of nationwide epidemiological survey.
World J Gastroenterol 2017;23:2826e31.
[31] Nakaharai K, Morita K, Jo T, Matsui H, Fushimi K, Yasunaga H. Early prophy-
lactic antibiotics for severe acute pancreatitis: a population-based cohort
study using a nationwide database in Japan. J Infect Chemother 2018
Sep;24(9):753e8.
[32] Lankisch PG, Weber-Dany B, Lerch MM. Clinical perspectives in pancreatol-
ogy: compliance with acute pancreatitis guidelines in Germany. Pancreatol-
ogy 2005;5:591e3.
[33] Foitzik T, Klar E. (non-)compliance with guidelines for the management of
severe acute pancreatitis among German surgeons. Pancreatology 2007;7:
80e5.
[34] Sekimoto M, Shikata S, Takada T, Hirata K, Yoshida M, Hirota M, et al. Changes
in management of acute pancreatitis before and after the publication of
evidence-based practice guidelines in 2003. J Hepatobiliary Pancreatol Sci
2010;17:17e23.
[35] Sun E, Tharakan M, Kapoor S, Chakravarty R, Salhab A, Buscaglia JM, et al. Poor
compliance with acg guidelines for nutrition and antibiotics in the manage-
ment of acute pancreatitis: a north american survey of gastrointestinal spe-
cialists and primary care physicians. JOP 2013;14:221e7.
[36] Rebours V, Levy P, Bretagne JF, Bommelaer G, Hammel P, Ruszniewski P. Do
guidelines inﬂuence medical practice? Changes in management of acute
pancreatitis 7 years after the publication of the French guidelines. Eur J
Gastroenterol Hepatol 2012;24:143e8.
[37] Lykkegaard J, Andersen MKK, Nexoe J, Hvidt EA. Defensive medicine in pri-
mary health care. Scand J Prim Health Care 2018:1e2.
[38] Panella M, Rinaldi C, Leigheb F, Knesse S, Donnarumma C, Kul S, et al. Prev-
alence and costs of defensive medicine: a national survey of Italian physicians.
J Health Serv Res Policy 2017;22:211e7.
[39] Assing Hvidt E, Lykkegaard J, Pedersen LB, Pedersen KM, Munck A,
Andersen MK. How is defensive medicine understood and experienced in a
primary care setting? A qualitative focus group study among Danish general
practitioners. BMJ Open 2017;7:e019851.
[40] Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al.
Preferred reporting items for systematic review and meta-analysis protocols
(prisma-p) 2015 statement. Syst Rev 2015;4:1.
[41] von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP.
The strengthening the reporting of observational studies in epidemiology
(strobe) statement: guidelines for reporting observational studies. PLoS Med
2007;4:e296.
[42] Qu R, Ji Y, Ling Y, Ye CY, Yang SM, Liu YY, et al. Procalcitonin is a good tool to
guide duration of antibiotic therapy in patients with severe acute pancreatitis.
A randomized prospective single-center controlled trial. Saudi Med J 2012;33:
382e7.
[43] Barreda L, Targarona J, Milian W, Portugal J, Sequeiros J, Pando E, et al. [is the
prophylactic antibiotic therapy with imipenem effective for patients with
pancreatic necrosis?]. Acta Gastroenterol Latinoam 2009;39:24e9.
[44] Bassi C, Falconi M, Talamini G, Uomo G, Papaccio G, Dervenis C, et al.
Controlled clinical trial of peﬂoxacin versus imipenem in severe acute
pancreatitis. Gastroenterology 1998;115:1513e7.
[45] Craig RM, Dordal E, Myles L, Letter. The use of ampicillin in acute pancreatitis.
Ann Intern Med 1975;83:831e2.
[46] Delcenserie R, Yzet T, Ducroix JP. Prophylactic antibiotics in treatment of se-
vere acute alcoholic pancreatitis. Pancreas 1996;13:198e201.
[47] Dellinger EP, Tellado JM, Soto NE, Ashley SW, Barie PS, Dugernier T, et al. Early
antibiotic treatment for severe acute necrotizing pancreatitis: a randomized,
double-blind, placebo-controlled study. Ann Surg 2007;245:674e83.
[48] Finch WT, Sawyers JL, Schenker S. A prospective study to determine the ef-
ﬁcacy of antibiotics in acute pancreatitis. Ann Surg 1976;183:667e71.
[49] Garcia-Barrasa A, Borobia FG, Pallares R, Jorba R, Poves I, Busquets J, et al.
A double-blind, placebo-controlled trial of ciproﬂoxacin prophylaxis in pa-
tients with acute necrotizing pancreatitis. J Gastrointest Surg 2009;13:
768e74.
[50] Howes R, Zuidema GD, Cameron JL. Evaluation of prophylactic antibiotics in
acute pancreatitis. J Surg Res 1975;18:197e200.
[51] Isenmann R, Runzi M, Kron M, Kahl S, Kraus D, Jung N, et al. Prophylactic
antibiotic treatment in patients with predicted severe acute pancreatitis: a
placebo-controlled, double-blind trial. Gastroenterology 2004;126:997e1004.
[52] Luiten EJ, Hop WC, Lange JF, Bruining HA. Controlled clinical trial of selective
decontamination for the treatment of severe acute pancreatitis. Ann Surg
1995;222:57e65.
[53] Manes G, Rabitti PG, Menchise A, Riccio E, Balzano A, Uomo G. Prophylaxis
with meropenem of septic complications in acute pancreatitis: a randomized,
controlled trial versus imipenem. Pancreas 2003;27:e79e83.
[54] Manes G, Uomo I, Menchise A, Rabitti PG, Ferrara EC, Uomo G. Timing ofantibiotic prophylaxis in acute pancreatitis: a controlled randomized study
with meropenem. Am J Gastroenterol 2006;101:1348e53.
[55] Nordback I, Sand J, Saaristo R, Paajanen H. Early treatment with antibiotics
reduces the need for surgery in acute necrotizing pancreatitis–a single-center
randomized study. J Gastrointest Surg 2001;5:113e8. discussion 118-120.
[56] Pederzoli P, Bassi C, Vesentini S, Campedelli A. A randomized multicenter
clinical trial of antibiotic prophylaxis of septic complications in acute necro-
tizing pancreatitis with imipenem. Surg Gynecol Obstet 1993;176:480e3.
[57] Rokke O, Harbitz TB, Liljedal J, Pettersen T, Fetvedt T, Heen LO, et al. Early
treatment of severe pancreatitis with imipenem: a prospective randomized
clinical trial. Scand J Gastroenterol 2007;42:771e6.
[58] Schwarz M, Isenmann R, Meyer H, Beger HG. [antibiotic use in necrotizing
pancreatitis. Results of a controlled study]. Dtsch Med Wochenschr 1997;122:
356e61.
[59] Xue P, Deng LH, Zhang ZD, Yang XN, Wan MH, Song B, et al. Effect of antibiotic
prophylaxis on acute necrotizing pancreatitis: results of a randomized
controlled trial. J Gastroenterol Hepatol 2009;24:736e42.
[60] Yang XN, Deng LH, Xue P, Zhao L, Jin T, Wan MH, et al. [non-preventive use of
antibiotics in patients with severe acute pancreatitis treated with integrated
traditional Chinese and western medicine therapy: a randomized controlled
trial]. Zhong Xi Yi Jie He Xue Bao 2009;7:330e3.
[61] Maravi-Poma E, Gener J, Alvarez-Lerma F, Olaechea P, Blanco A, Dominguez-
Munoz JE. Early antibiotic treatment (prophylaxis) of septic complications in
severe acute necrotizing pancreatitis: a prospective, randomized, multicenter
study comparing two regimens with imipenem-cilastatin. Intensive Care Med
2003;29:1974e80.
[62] Spicak J, Hubaczova M, Antos F. Antibiotics in the treatment of acute
pancreatitis - ﬁndings from a randomized multi-centre prospective study.
Ceska Slov Gastroenterol Hepatol 2002;56:183e9.
[63] Spicak J, Hejtmankova S, Hubaczova M. Antibiotic prophylaxis of infectious
complications of acute pancreatitis - the results of randomised study by
meropenem. Ceska Slov Gastroenterol Hepatol 2003;57:222e7.
[64] Powell JJ, Campbell E, Johnson CD, Siriwardena AK. Survey of antibiotic pro-
phylaxis in acute pancreatitis in the UK and Ireland. Br J Surg 1999;86:320e2.
[65] King NK, Siriwardena AK. European survey of surgical strategies for the
management of severe acute pancreatitis. Am J Gastroenterol 2004;99:
719e28.
[66] Mayumi T, Ura H, Arata S, Kitamura N, Kiriyama I, Shibuya K, et al. Evidence-
based clinical practice guidelines for acute pancreatitis: Proposals.
J Hepatobiliary Pancreatol Surg 2002;9:413e22.
[67] Takeda K, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, et al. Jpn
guidelines for the management of acute pancreatitis: medical management of
acute pancreatitis. J Hepatobiliary Pancreatol Surg 2006;13:42e7.
[68] Werge M, Novovic S, Schmidt PN, Gluud LL. Infection increases mortality in
necrotizing pancreatitis: a systematic review and meta-analysis. Pancreatol-
ogy 2016;16:698e707.
[69] Guo Q, Li A, Xia Q, Liu X, Tian B, Mai G, et al. The role of organ failure and
infection in necrotizing pancreatitis: a prospective study. Ann Surg 2014;259:
1201e7.
[70] Schepers NJ, Bakker OJ, Besselink MG, Ahmed Ali U, Bollen TL, Gooszen HG,
et al. Impact of characteristics of organ failure and infected necrosis on
mortality in necrotising pancreatitis. Gut 2018;0:1e8. https://doi.org/
10.1136/gutjnl-2017-314657 (PMID: 29950344).
[71] de Vries AC, Besselink MG, Buskens E, Ridwan BU, Schipper M, van
Erpecum KJ, et al. Randomized controlled trials of antibiotic prophylaxis in
severe acute pancreatitis: relationship between methodological quality and
outcome. Pancreatology 2007;7:531e8.
[72] Moggia E, Koti R, Belgaumkar AP, Fazio F, Pereira SP, Davidson BR, et al.
Pharmacological interventions for acute pancreatitis. Cochrane Database Syst
Rev 2017;4:CD011384.
[73] Stirling AD, Moran NR, Kelly ME, Ridgway PF, Conlon KC. The predictive value
of c-reactive protein (crp) in acute pancreatitis - is interval change in crp an
additional indicator of severity? HPB (Oxford) 2017;19:874e80.
[74] Puolakkainen P, Valtonen V, Paananen A, Schroder T. C-reactive protein (crp)
and serum phospholipase a2 in the assessment of the severity of acute
pancreatitis. Gut 1987;28:764e71.
[75] Panek J, Kusnierz-Cabala B, Dolecki M, Pietron J. Serum proinﬂammatory
cytokine levels and white blood cell differential count in patients with
different degrees of severity of acute alcoholic pancreatitis. Pol Przegl Chir
2012;84:230e7.
[76] Bierma MJ, Coffey MJ, Nightingale S, van Rheenen PF, Ooi CY. Predicting severe
acute pancreatitis in children based on serum lipase and calcium: a multi-
centre retrospective cohort study. Pancreatology 2016;16:529e34.
[77] Kumaravel A, Stevens T, Papachristou GI, Muddana V, Bhatt A, Lee PJ, et al.
A model to predict the severity of acute pancreatitis based on serum level of
amylase and body mass index. Clin Gastroenterol Hepatol 2015;13:1496e501.
[78] Fabre A, Boulogne O, Gaudart J, Mas E, Olives JP, Sarles J. Evaluation of serum
lipase as predictor of severity of acute pancreatitis in children. J Pediatr
Gastroenterol Nutr 2014;58:e41e2.
[79] Devanath A, Kumari J, Joe J, Peter S, Rajan S, Sabu L, et al. Usefulness of lipase/
amylase ratio in acute pancreatitis in south indian population. Indian J Clin
Biochem 2009;24:361e5.
